Context Therapeutics Inc. (CNTX)
Context Therapeutics Statistics
Share Statistics
Context Therapeutics has 89.7M shares outstanding. The number of shares has increased by 19.61% in one year.
| Shares Outstanding | 89.7M |
| Shares Change (YoY) | 19.61% |
| Shares Change (QoQ) | 19.61% |
| Owned by Institutions (%) | 90.44% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 366 |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 2.35M, so 2.61% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 2.61% |
| Short % of Float | 3.17% |
| Short Ratio (days to cover) | 6.2 |
Valuation Ratios
The PE ratio is -2.3 and the forward PE ratio is -2.55. Context Therapeutics's PEG ratio is 0.03.
| PE Ratio | -2.3 |
| Forward PE | -2.55 |
| PS Ratio | 0 |
| Forward PS | 1.4 |
| PB Ratio | 0.64 |
| P/FCF Ratio | -2.09 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Context Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.62, with a Debt / Equity ratio of 0.
| Current Ratio | 35.62 |
| Quick Ratio | 35.62 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-2,227,092 |
| Employee Count | 12 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.29% in the last 52 weeks. The beta is 2.18, so Context Therapeutics's price volatility has been higher than the market average.
| Beta | 2.18 |
| 52-Week Price Change | -50.29% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 1.52 |
| Relative Strength Index (RSI) | 52.96 |
| Average Volume (20 Days) | 155,834 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.92M |
| Net Income | -26.73M |
| EBITDA | -26.67M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.46 |
Balance Sheet
The company has 94.43M in cash and 219.38K in debt, giving a net cash position of 94.21M.
| Cash & Cash Equivalents | 94.43M |
| Total Debt | 219.38K |
| Net Cash | 94.21M |
| Retained Earnings | -94.78M |
| Total Assets | 98.13M |
| Working Capital | 95.15M |
Cash Flow
In the last 12 months, operating cash flow was -14.56M and capital expenditures -14.76M, giving a free cash flow of -29.31M.
| Operating Cash Flow | -14.56M |
| Capital Expenditures | -14.76M |
| Free Cash Flow | -29.31M |
| FCF Per Share | -0.5 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CNTX is $5, which is 474.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $5 |
| Price Target Difference | 474.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 13.59 |
| Piotroski F-Score | 2 |